GSK 2190914

Drug Profile

GSK 2190914

Alternative Names: 2190914; AM103; GSK-2190914

Latest Information Update: 14 Oct 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amira Pharmaceuticals
  • Developer Amira Pharmaceuticals; GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Cardiovascular disorders

Most Recent Events

  • 14 Oct 2014 Discontinued - Phase-I for Cardiovascular disorders in Europe (PO)
  • 14 Oct 2014 Discontinued - Phase-II for Asthma in Europe (PO)
  • 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top